However, using the noncovalent scaffolding LSD1 inhibitor (SP-2509 and clinical successor SP-2577, also known as seclidemstat), we observed significant synergy with JAKi (Ruxolitinib, 0–10 uM) (Fig. 6B) and with the BCL2 inhibitor (ABT-199, 0–600 nM) (Fig. S8C) in selectively reducing the growth of LOUCY ETP-ALL cells but not the mature T-ALL JURKAT cells. The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.